|
Characterization of the benefit-risk profile of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naïve advanced renal cell carcinoma (aRCC; CheckMate 214). |
|
|
Honoraria - Argos Therapeutics; Bristol-Myers Squibb; Calithera Biosciences; Exelixis; Nektar; Novartis; Pfizer |
Consulting or Advisory Role - Argos Therapeutics; Bristol-Myers Squibb; Calithera Biosciences; Exelixis; Nektar; Novartis; Pfizer |
Research Funding - Bristol-Myers Squibb; Epizyme; Exelixis; Mirati Therapeutics; Novartis |
Travel, Accommodations, Expenses - Argos Therapeutics; Argos Therapeutics; Bristol-Myers Squibb; Calithera Biosciences; Exelixis; Nektar; Novartis; Pfizer |
|
|
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; exelixis; Pfizer |
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst) |
|
|
Consulting or Advisory Role - Merck |
Speakers' Bureau - Bristol-Myers Squibb; Merck; Pfizer |
Research Funding - Bristol-Myers Squibb; Merck |
|
|
Honoraria - Astellas Pharma; Bayer Health; Bristol-Myers Squibb; Hexal; Janssen-Cilag; Jenapharm; Pfizer; Pierre Fabre; Sanofi; Teva |
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer Health; Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Pfizer; Sanofi |
Research Funding - Bristol-Myers Squibb; Novartis |
|
|
Consulting or Advisory Role - Corvus Pharmaceuticals; Merck; Pfizer |
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst) |
Travel, Accommodations, Expenses - Pfizer |
|
|
No Relationships to Disclose |
|
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
Research Funding - Bristol-Myers Squibb (Inst) |
|
Christian K. Kollmannsberger |
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer |
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Novartis; Pfizer; Seagen |
Travel, Accommodations, Expenses - Novartis; Pfizer |